{"entity":{"id":"egfr","kind":"target","name":"EGFR","aka":[],"tldr":"A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.","summary":"EGFR activating mutations (exon 19 del, L858R) drive ~15% of Western and ~40-50% of East Asian NSCLC; osimertinib is standard first-line. EGFR is also an antibody target in colorectal and head-and-neck cancer (cetuximab, panitumumab) and a component of bispecifics (amivantamab, EGFR×MET; EGFR×HER3 ADCs). Resistance via C797S, MET amplification, and histologic transformation is the central problem.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"}],"tags":["driver","kinase"],"related":["egfr-exon-19-deletion","egfr-l858r","egfr-exon-20-insertion","egfr-t790m","egfr-c797s"],"cancers":["nsclc","colorectal","head-and-neck","glioblastoma","tnbc","gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":["dacomitinib","mobocertinib","guardant360-cdx","oncomine-dx-target-test","therascreen-cdx","tempus-xt-cdx","necitumumab","hlx43","zipalertinib","jmt101","hs-20117","mcla-129","tqb6411","tqb2930","tqb2922","e-edv-d682","hmbd-001","silevertinib","vrn110755","js111"],"companies":["bicara-therapeutics","imagene-ai","inivata","lucence","oric-pharmaceuticals"],"institutions":[],"pathways":["ras-mapk","pi3k-akt-mtor","breast-cancer-signalling","choline-metabolism-in-cancer","colorectal-cancer-signalling","glioma-signalling","nsclc-signalling","prostate-cancer-signalling"],"terms":["sidedness","wild-type","egfr-mutation-subtypes","egfr-exon19-l858r","egfr-exon20-insertion"],"trials":["nct06043817","nct06567015","nct06975410","nct05394831","nct05168566","nct07467863","nct06080776","nct06616766","nct07136779","nct07641023","nct05920135","nct06940401","nct06010329"],"people":[],"bottlenecks":[],"keyPapers":["paper-tcga-breast-molecular-portraits-nature-2012","paper-lehmann-tnbc-subtypes-jci-2011","paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","paper-erices-chilean-gallbladder-landscape-front-oncol-2025","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-tcga-lung-adenocarcinoma-nature-2014","paper-lindeman-lung-molecular-testing-guideline-jto-2018"],"journals":[],"dependsOn":[],"notes":["Triple-negative breast cancer: EGFR is amplified or gained in 23% of basal-like tumours but rarely mutated (Cancer Genome Atlas 2012), high-level amplification 3 to 6% by cohort (cBioPortal); EGFR-directed antibodies failed unselected, and the receptor now matters as one arm of the EGFR-HER3 bispecific antibody-drug conjugate izalontamab brengitecan.","Colorectal cancer: a target without an alteration. Cetuximab and panitumumab work in RAS and BRAF wild-type, left-sided disease regardless of EGFR copy number or expression, and no EGFR test selects them; the biomarkers are negative ones (Karapetis 2008, Douillard 2013) plus primary tumour side (Arnold 2017). High-level EGFR amplification is 1 to 2% (cBioPortal) and epiregulin overexpression marks the distal, ligand-dependent tumours (Missiaglia 2014). Acquired resistance is read in plasma as emerging KRAS, NRAS, BRAF and EGFR ectodomain alterations, detectable months before imaging (Misale 2012, Diaz 2012).","Lung cancer: mutated in 12.4% of resected Western adenocarcinoma and 47.4% of East Asian adenocarcinoma, with 28.4% in never-smoker whole genomes (cBioPortal), the widest ancestry gap of any biomarker in solid-tumour oncology. The class matters more than the gene: exon 19 deletions (about 14% of adenocarcinomas) and L858R (about 11%) respond to every generation of inhibitor, exon 20 insertions (about 2%) respond to none of them and need different medicines, and the uncommon G719X, L861Q and S768I alleles do better on a second-generation irreversible inhibitor than on a first-generation one. Resistance is read in the same gene: T790M in 63% of rebiopsies after a first-generation inhibitor (Yu 2013) and C797S in 22% after osimertinib, where the allelic phase with T790M decides whether a combination can cover it (Thress 2015, Oxnard 2018). Immunohistochemistry is not acceptable for EGFR testing (Lindeman 2018)."],"symbol":"EGFR","role":[],"sources":[],"specificity":"tumour-specific","distribution":"many-types","specificityNote":"Tumour-specific alteration: 4 of 4 label readouts filed under it measure a sequence variant (EGFR exon 19 deletion, EGFR exon 20 insertion, EGFR L858R, EGFR T790M) absent from normal cells. HPA EGFR: RNA tissue enhanced (placenta 62 nTPM); high antibody staining in 4 normal tissues; highest cancer staining head and neck cancer (4 of 4 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Colorectal cancer, Head and neck squamous cell carcinoma, Brain and spinal cord tumours (all types), Biliary tract cancer (all types)); approvals of single-target medicines aimed at it also list Pancreatic ductal adenocarcinoma, Oesophageal cancer, not counted; Open Targets associates it with 17 specific cancer types at or above 0.5 (non-small cell lung carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, lung cancer, breast cancer, colorectal adenocarcinoma and more). (Rule 3 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"EGFR exon 19 deletion label threshold","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7","note":"EGFR exon 19 deletion or exon 21 L858R"},{"label":"EGFR exon 20 insertion label threshold","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1466c070-9f97-4fa4-a955-6a6b59981fb8","note":"EGFR exon 20 insertion"},{"label":"Human Protein Atlas EGFR tissue","url":"https://www.proteinatlas.org/ENSG00000146648-EGFR/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000146648 associations","url":"https://platform.opentargets.org/target/ENSG00000146648/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3236","ensembl":"ENSG00000146648","uniprot":"P00533","entrez":"1956","firstDescribed":1984,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Ullrich et al, Nature, 1984, \"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/6328312/","biology":"EGFR is a receptor tyrosine kinase activating RAS-MAPK and PI3K-AKT. Exon 20 insertions need dedicated drugs.","whereFound":["NSCLC (mutations)","Colorectal (wild-type, antibody target)","Head and neck squamous","Glioblastoma (amplification, EGFRvIII)","Triple-negative breast cancer: amplification 3-6%","Colorectal cancer: high-level amplification (and acquired ectodomain mutation) 1-2%","Gallbladder cancer: amplification or mutation 1-3%","Non-small-cell lung cancer: activating mutation (any class) 12-47%","Non-small-cell lung cancer: in-frame deletion around codons 746 to 750 13-19%","Non-small-cell lung cancer: exon 21 point mutation 9-21%","Non-small-cell lung cancer: in-frame insertion or duplication in the loop after the c-helix 1-3%","Non-small-cell lung cancer: g719x, l861q, s768i and compound alleles 3-5%"],"targetClass":"kinase","prevalence":[{"cancerId":"nsclc","pct":"10-15","measure":"Activating mutation (US/Europe)","source":"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018","note":"40-50% in East Asian adenocarcinoma"},{"cancerId":"colorectal","pct":100,"measure":"Wild-type EGFR is the antibody target","source":"https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor","note":"Benefit restricted to RAS/BRAF wild-type (~40%)"},{"cancerId":"head-and-neck","pct":"80-90","measure":"Overexpression by IHC","source":"https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor"},{"cancerId":"glioblastoma","pct":"40-50","measure":"Amplification","source":"https://www.cbioportal.org/study/summary?id=gbm_tcga_pan_can_atlas_2018","note":"EGFRvIII in ~25-30%"},{"cancerId":"tnbc","pct":"3-6","measure":"Amplification","source":"https://doi.org/10.1038/nature11412","note":"EGFR amplified (gains included) in 23% of basal-like tumours, alongside PIK3CA 49%, KRAS 32% and BRAF 30% (Cancer Genome Atlas 2012); cBioPortal high-level amplification: 5 of 119, 4.2%, in brca_tcga_pan_can_atlas_2018; 19 of 320, 5.9%, in brca_metabric; 5 of 176, 2.8%, in breast_msk_2018. Growth-factor signalling defines the BL2 subtype (Lehmann 2011)."},{"cancerId":"colorectal","pct":"1-2","measure":"High-level amplification (and acquired ectodomain mutation)","source":"https://www.cbioportal.org/study/summary?id=crc_msk_2026","note":"cBioPortal high-level amplification: 101 of 7,237, 1.4%, in crc_msk_2026; 16 of 1,134, 1.4%, in crc_msk_2017; 19 of 1,516 in crc_eo_2020; 4 of 592 in coadread_tcga_pan_can_atlas_2018. Distal tumours are the ones that carry EGFR or HER2 amplification and overexpress epiregulin (Missiaglia 2014)."},{"cancerId":"gallbladder","pct":"1-3","measure":"Amplification or mutation","source":"https://www.cbioportal.org/study/summary?id=gbc_mskcc_2022","note":"Amplification in 8 of 244 samples, 3.3%, and mutation in 3 of 244, 1.2%, in cBioPortal gbc_mskcc_2022; 3.1% of 32 exomes in gbc_shanghai_2014; among the actionable variants in the Chilean cohort (Erices 2025)."},{"cancerId":"nsclc","pct":"12-47","measure":"Activating mutation (any class)","source":"https://www.cbioportal.org/study/summary?id=luad_oncosg_2020","note":"cBioPortal: 143 of 302, 47.4%, in luad_oncosg_2020 (East Asian); 866 of 2,653, 32.6%, in luad_mskcc_2023_met_organotropism; 268 of 915, 29.3%, in lung_msk_2017; 66 of 232, 28.4%, in lung_nci_2022 (never smokers); 662 of 2,621, 25.3%, in nsclc_ctdx_msk_2022; 38 of 110, 34.5%, in luad_cptac_2020; 70 of 566, 12.4%, in luad_tcga_pan_can_atlas_2018; 33 of 230, 14.3%, in luad_tcga_pub. The Lung Cancer Mutation Consortium found sensitising EGFR in 122 of 733, 17%, plus other EGFR mutations in 29 (Kris 2014)."},{"cancerId":"nsclc","pct":"13-19","measure":"In-frame deletion around codons 746 to 750","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal, samples carrying the class: 382 of 2,653, 14.4%, in luad_mskcc_2023_met_organotropism; 308 of 2,621, 11.8%, in nsclc_ctdx_msk_2022; 117 of 915, 12.8%, in lung_msk_2017; 57 of 302, 18.9%, in luad_oncosg_2020; 38 of 232, 16.4%, in lung_nci_2022; 23 of 566, 4.1%, in luad_tcga_pan_can_atlas_2018. E746_A750del is the single commonest variant (237 of 1,114 EGFR records in luad_mskcc_2023_met_organotropism)."},{"cancerId":"nsclc","pct":"9-21","measure":"Exon 21 point mutation","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal, samples: 289 of 2,653, 10.9%, in luad_mskcc_2023_met_organotropism; 206 of 2,621, 7.9%, in nsclc_ctdx_msk_2022; 82 of 915, 9.0%, in lung_msk_2017; 63 of 302, 20.9%, in luad_oncosg_2020; 20 of 232, 8.6%, in lung_nci_2022; 23 of 566, 4.1%, in luad_tcga_pan_can_atlas_2018."},{"cancerId":"nsclc","pct":"1-3","measure":"In-frame insertion or duplication in the loop after the C-helix","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal, samples: 47 of 2,653, 1.8%, in luad_mskcc_2023_met_organotropism; 45 of 2,621, 1.7%, in nsclc_ctdx_msk_2022; 17 of 915, 1.9%, in lung_msk_2017; 4 of 232, 1.7%, in lung_nci_2022; 3 of 302, 1.0%, in luad_oncosg_2020. About 5 to 6% of EGFR-mutant lung adenocarcinoma."},{"cancerId":"nsclc","pct":"3-5","measure":"G719X, L861Q, S768I and compound alleles","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal, samples out of 2,653 in luad_mskcc_2023_met_organotropism: G719X 57 (2.1%), L861Q 30 (1.1%), S768I 30 (1.1%); out of 2,621 in nsclc_ctdx_msk_2022: G719X 28, S768I 19, L861Q 15; out of 915 in lung_msk_2017: G719X 14, L861Q 8, S768I 5. Together they are 117 of 2,653 samples, 4.4%, in the largest cohort."}]},"route":"/targets/egfr/","neighbours":{"biomarker":[{"id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/"},{"id":"egfr-exon-19-deletion","kind":"biomarker","name":"EGFR exon 19 deletion","route":"/biomarkers/egfr-exon-19-deletion/"},{"id":"egfr-exon-20-insertion","kind":"biomarker","name":"EGFR exon 20 insertion","route":"/biomarkers/egfr-exon-20-insertion/"},{"id":"egfr-l858r","kind":"biomarker","name":"EGFR L858R","route":"/biomarkers/egfr-l858r/"},{"id":"egfr-t790m","kind":"biomarker","name":"EGFR T790M","route":"/biomarkers/egfr-t790m/"}],"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/"},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/"},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/"},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/"},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"drug":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/"},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/"},{"id":"cobas-egfr-mutation-test","kind":"drug","name":"cobas EGFR Mutation Test v2","route":"/drugs/cobas-egfr-mutation-test/"},{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/"},{"id":"depatuxizumab-mafodotin","kind":"drug","name":"Depatuxizumab mafodotin","route":"/drugs/depatuxizumab-mafodotin/"},{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/"},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/"},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"},{"id":"guardant360-cdx","kind":"drug","name":"Guardant360 CDx","route":"/drugs/guardant360-cdx/"},{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/"},{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/"},{"id":"hs-20117","kind":"drug","name":"HS-20117","route":"/drugs/hs-20117/"},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/"},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"},{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/"},{"id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/"},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"},{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/"},{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/"},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/"},{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"},{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/"},{"id":"oncomine-dx-target-test","kind":"drug","name":"Oncomine Dx Target Test","route":"/drugs/oncomine-dx-target-test/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/"},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/"},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"},{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/"},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/"},{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/"},{"id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/"},{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/"},{"id":"tqb2922","kind":"drug","name":"TQB2922","route":"/drugs/tqb2922/"},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/"},{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/"},{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/"},{"id":"varlitinib","kind":"drug","name":"Varlitinib","route":"/drugs/varlitinib/"},{"id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/"},{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/"}],"company":[{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/"},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/"},{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/"},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/"},{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/"},{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/"},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/"}],"pathway":[{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/"},{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/"},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/"},{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/"},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/"},{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/"},{"id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/"},{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"},{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/"},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/"},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/"},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/"},{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/"}],"term":[{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/"},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/"},{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/"},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/"},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/"},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/"},{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/"},{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/"},{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/"},{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/"},{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/"},{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/"},{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/"},{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/"},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/"},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/"},{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/"},{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/"},{"id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/"},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/"},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/"},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/"},{"id":"wild-type","kind":"term","name":"Wild-type (WT)","route":"/terms/wild-type/"}],"trial":[{"id":"nct05394831","kind":"trial","name":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","route":"/trials/nct05394831/"},{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/"},{"id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/"},{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/"},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/"},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/"},{"id":"n0147","kind":"trial","name":"Alliance N0147","route":"/trials/n0147/"},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/"},{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/"},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/"},{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/"},{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/"},{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/"},{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/"},{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/"},{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/"},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/"},{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/"},{"id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/"},{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/"},{"id":"nct05920135","kind":"trial","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","route":"/trials/nct05920135/"},{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/"},{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/"},{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/"},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/"},{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","route":"/trials/gefitinib-chemo-tmh/"},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/"},{"id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/"},{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/"},{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/"},{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/"},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/"},{"id":"coin","kind":"trial","name":"MRC COIN","route":"/trials/coin/"},{"id":"co-17","kind":"trial","name":"NCIC CO.17","route":"/trials/co-17/"},{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/"},{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/"},{"id":"opus","kind":"trial","name":"OPUS","route":"/trials/opus/"},{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/"},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/"},{"id":"petacc-8","kind":"trial","name":"PETACC-8","route":"/trials/petacc-8/"},{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/"},{"id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/"},{"id":"squire","kind":"trial","name":"SQUIRE","route":"/trials/squire/"},{"id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/"},{"id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/"},{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/"},{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/"}],"paper":[{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/"},{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/"},{"id":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","kind":"paper","name":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","route":"/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/"},{"id":"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","kind":"paper","name":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/"},{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/"},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/"},{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/"},{"id":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","kind":"paper","name":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","route":"/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/"},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/"},{"id":"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","kind":"paper","name":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","route":"/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/"},{"id":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","kind":"paper","name":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","route":"/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/"},{"id":"paper-lee-clonal-history-small-cell-transformation-jco-2017","kind":"paper","name":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","route":"/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/"},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/"},{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/"},{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/"},{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/"},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/"},{"id":"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","kind":"paper","name":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","route":"/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/"},{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/"},{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/"},{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/"},{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/"},{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/"},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/"},{"id":"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","kind":"paper","name":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)","route":"/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/"},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/"},{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/"},{"id":"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","kind":"paper","name":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","route":"/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/"},{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/"},{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/"},{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/"},{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/"},{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/"},{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/"},{"id":"paper-lenz-cms-calgb-swog-80405-jco-2019","kind":"paper","name":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","route":"/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/"},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/"},{"id":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kind":"paper","name":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","route":"/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/"},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/"},{"id":"paper-krystal-1-crc-yaeger-nejm-2023","kind":"paper","name":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","route":"/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/"},{"id":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","kind":"paper","name":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","route":"/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/"},{"id":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","kind":"paper","name":"Lung adenocarcinoma promotion by air pollutants","route":"/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"},{"id":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","kind":"paper","name":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","route":"/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/"},{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/"},{"id":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","kind":"paper","name":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","route":"/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/"},{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/"},{"id":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","kind":"paper","name":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","route":"/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/"},{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/"},{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/"},{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/"},{"id":"paper-douillard-prime-panitumumab-ras-nejm-2013","kind":"paper","name":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)","route":"/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/"},{"id":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","kind":"paper","name":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","route":"/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/"},{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/"},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/"},{"id":"paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","kind":"paper","name":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","route":"/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/"},{"id":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","kind":"paper","name":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","route":"/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/"},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/"},{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/"},{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/"},{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/"},{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/"}],"pairing":[{"id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/"},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/"},{"id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/"},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/"}],"technology":[{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"idea":[{"id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/"},{"id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/"},{"id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/"},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/"},{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/"},{"id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/"},{"id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/"},{"id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/"},{"id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/"},{"id":"idea-lung-never-smoker-disease-its-own-programme","kind":"idea","name":"Treat lung cancer in never-smokers as its own disease, with its own detection programme","route":"/ideas/idea-lung-never-smoker-disease-its-own-programme/"},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}],"target":[{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/"}],"person":[{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/"},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/"},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/"},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/"},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/"},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/"},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/"},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/"},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/"},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/"},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/"},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/"},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/"},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/"},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/"},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/"},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/"},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/"},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/"},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/"},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/"},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/"},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/"},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/"},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/"}],"bottleneck":[{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"}],"collection":[{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/"}],"institution":[{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/"},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/"},{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/"},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/"},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/"},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/"},{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/"},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/"},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/"},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/"},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/"}]}}